פינלנד - פינית - Fimea (Suomen lääkevirasto)

bracco imaging spa - iomeprol - injektioneste, liuos - 350 mg i/ml - jomeproli

פינלנד - פינית - Fimea (Suomen lääkevirasto)

bracco imaging spa - iomeprol - injektioneste, liuos - 400 mg i/ml - jomeproli

פינלנד - פינית - Fimea (Suomen lääkevirasto)

guerbet - ioversol - injektio-/infuusioneste, liuos - 240 mg i/ml - joversoli

פינלנד - פינית - Fimea (Suomen lääkevirasto)

guerbet - ioversol - injektio-/infuusioneste, liuos - 300 mg i/ml - joversoli

פינלנד - פינית - Fimea (Suomen lääkevirasto)

guerbet - ioversol - injektio-/infuusioneste, liuos - 320 mg i/ml - joversoli

פינלנד - פינית - Fimea (Suomen lääkevirasto)

guerbet - ioversol - injektio-/infuusioneste, liuos - 350 mg i/ml - joversoli

האיחוד האירופי - פינית - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressantit - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

האיחוד האירופי - פינית - EMA (European Medicines Agency)

pinax pharma gmbh - joflupaani (123i) - radionuclide imaging; dementia; movement disorders - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. aikuisilla potilailla, auttaa erottamaan todennäköinen dementia lewyn kappale-alzheimerin tauti.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

פינלנד - פינית - Fimea (Suomen lääkevirasto)

poa pharma scandinavia ab - fluocinolone acetonide, ciprofloxacin hydrochloride - korvatipat, liuos - 3 mg/ml + 0,25 mg/ml - fluosinoloniasetonidi ja mikrobilääkkeet

פינלנד - פינית - Fimea (Suomen lääkevirasto)

poa pharma scandinavia ab - fluocinolone acetonide, ciprofloxacin hydrochloride - korvatipat, liuos, kerta-annospakkaus - 3 mg/ml + 0,25 mg/ml - fluosinoloniasetonidi ja mikrobilääkkeet